帕金森动力图对早期帕金森病患者运动功能的量化研究

目的利用帕金森动力图系统(PKG)对帕金森病(PD)前驱期、初诊未服药早期PD患者的运动症状进行评估,探讨其对早期PD的辅助诊断价值。方法收集在南京市社区筛查的PD前驱期患者24例,在南京医科大学附属脑科医院PD专病门诊就诊的初诊未服药早期PD患者38例,根据患者有无静止性震颤将患者分为震颤阳性组和震颤阴性组。采用统一PD评定量表Ⅲ(UPDRSⅢ)评估运动症状,并计算UPDRSⅢ-T(不包括震颤评分)、同侧UPDRSⅢ和同侧UPDRSⅢ-T(同侧指症状明显侧)分值。患者佩戴PKG腕表,连续7 d记录数据,分析PKG参数运动迟缓评分(BKS)、震颤时间百分比(PTT)与临床PD量表的相关性,并对PTT进行ROC曲线分析。结果 BKS与UPDRSⅢ、UPDRSⅢ-T、同侧UPDRSⅢ、同侧UPDRSⅢ-T均呈正相关。回归分析显示,UPDRSⅢ为4时,BKS为26.66,大于健康人群BKS第75百分位数。ROC曲线分析显示,PTT预测静止性震颤的最佳界值为8.1%,敏感度为70.0%,特异度为92.9%。结论 PKG参数与运动症状评估量表具有良好相关性,可检测到轻微PD症状,建议作为PD早期运动症状的筛查工具。     

帕金森病患者血清脂联素水平与运动症状及非运动症状的相关性

目的 探讨帕金森病(PD)患者血清脂联素水平与运动症状以及非运动症状的相关性.方法 选取94例PD患者以及90名健康对照者,利用ELISA法检测PD患者及健康对照者血清脂联素水平,并记录PD患者的年龄、多巴丝肼片剂量,并对所有PD患者行帕金森病评价量表第三部分评分(UPDRSⅢ)、Hoehn-Yahr分期、ADL、Webster、疲劳严重度量表(FSS)、匹茨堡睡眠质量指数(PSQI)、自主神经功能量表(SCOPA-AUT)、汉密尔顿抑郁量表(HAMD)评估.结果 PD患者血清脂联素水平为(8.2士2.6)mg/L,明显低于健康对照组的(17.5±7.1)mg/L,且差异有统计学意义(t=-4.12,P＜0.01).脂联素水平与PD患者的UPDRSⅢ评分、H-Y分期、Webster评分、ADL评分及PSQI评分均呈负相关(r分别为-0.71,-0.82,-0.77,-0.64,-0.69;P＜ 0.05).结论 PD患者血清脂联素水平降低,且与PD患者的运动症状及非运动症状均有关.     

帕金森病运动症状进展分析

目的分析帕金森病(PD)患者运动症状进展特点。方法采用PD统一评分量表(UPDRS)Ⅲ对912例PD患者进行评估。结果与病程1年的患者比较,除病程1~2年的患者外,其他病程患者的UPDRSⅢ评分、强直分、姿势或步态异常分、轴性症状总分、言语分、步态分显著升高(均P0.05),病程5~6年及14年患者的震颤分,病程5~6年、7~8年、9~13年、14年患者的运动迟缓分、姿势分显著升高(P0.05~0.01)。轴性症状进展速度高于UPDRSⅢ评分。结论 PD患者病程早期UPDRSⅢ评分进展快,震颤症状进展独立于其他症状,轴性症状评分较UPDRSⅢ更敏感地反映疾病加重趋势。     

帕金森病患者自主神经功能障碍评估

目的：评估帕金森病（PD）患者中自主神经功能障碍症状发生比例、各症状分布的差异，及其与PD临床特点之间的关系。方法：应用SCOPA-AUT量表、统一帕金森病评分量表（UPDRS）、日常生活能力量表（ADL）、Hamilton抑郁量表和简易智能量表（MMSE）对116例原发性PD患者进行评估。结果：SCOPA-AUT总分和消化系统（GI）症状、排尿（UR）症状、体温调节（TH）症状、性功能（SX）症状评分均高于对照组，差异有极显著统计学意义（P=0．0001）。SCOPA-AUT总分与UPDRS评分、Hamilton抑郁量表评分呈正相关（P〈0．001），与生活质量ADL评分呈负相关（P〈0．001）。结论：自主神经功能障碍在PD早期就会出现，并随着疾病进展而加重，影响患者的生活质量。     

丘脑底核电刺激术对75岁以上帕金森病患者疗效

目的研究丘脑底核电刺激术(STN-DBS)对75岁以上帕金森病(PD)患者术后1年的疗效。方法选取2003年5月至2017年5月在我院接受STN-DBS治疗的10例75岁以上PD患者进行回顾性研究,分别于术前、术后3个月、6个月、12个月进行UPDRSⅢ及帕金森非运动评分。结果 10例患者术后随访1年,开机未服药与术前未服药状态相比,UPDRSⅢ、震颤、强直、迟缓及中轴症状评分均显著降低(P0.05)。术后1年帕金森患者非运动评分ADL、HAMD、PSQI评分显著降低(P0.05),MMSE、HAMA评分有所增加(P0.05)。结论STN-DBS能显著改善75岁以上PD患者的运动症状和部分非运动症状,提高患者生活质量,减少抗PD药物用量。但仍需长期随访以评价对高龄患者的疗效。     

新疆地区维、汉族帕金森病患者运动症状和非运动症状的特点

目的探讨新疆地区维、汉族帕金森病(PD)患者运动症状和非运动症状的特点。方法 226例汉族帕金森患者(汉族组)和389例维族帕金森患者(维族组)采用统一PD评定量表第三部分(UPDRSⅢ)评分进行运动症状评估;采用非运动症状筛查问卷(NMSQ)评估非运动症状,采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评估患者抑郁和焦虑状况,采用帕金森病睡眠量表(PDSS)评估患者睡眠状况,采用简易智能精神状态检查(MMSE)量表评分评估患者认知功能。对两组结果进行比较。结果维族组UPDRSⅢ评分(28.1±8.3)明显高于汉族组(18.1±2.4)(P0.05)。汉族组NMSQ评分明显高于维族组(P0.05),且汉族组非运动症状以夜尿、便秘、近记忆下降为主,而维族组非运动症状以夜尿、便秘、性欲改变为主。汉族组HAMD、HAMA评分明显高于维族组,PDSS评分明显低于维族组(均P0.05)。两组MMSE量表评分差异无统计学意义。结论维族PD患者运动症状较重,而汉族PD患者非运动症状较多;汉族PD患者焦虑、抑郁、睡眠状况较维族更为严重。     

帕金森病患者疲劳与睡眠障碍的研究

目的调查帕金森病(Parkinson’s disease,PD)患者中疲劳和睡眠障碍的患病率,研究疲劳和睡眠障碍的危险因素及相关性。方法采用疲劳严重度量表(FSS)和匹兹堡睡眠质量指数量表(PSQI)对363例PD患者的疲劳及睡眠状况进行评价。FSS4界定为疲劳,PSQI≥7界定为睡眠障碍。同时,采用统一帕金森病评分量表(UPDRS)及HoehnYahr评价运动障碍及严重程度,美国国立精神卫生研究所流行病学研究中心编制的抑郁量表(CESD)评价抑郁,阿尔茨海默病评定量表(ADAS-Cog)评价认知,36条目简化医疗结局调查问卷(SF-36)评价生活质量。结果 363例PD患者61.7%存在疲劳,55.1%存在睡眠障碍。其中,136例(37.5%)疲劳与睡眠障碍共存,87例(24%)仅存在疲劳,63例(17%)仅存在睡眠障碍。单因素方差分析显示,疲劳组与对照组比较UPDRS第3部分评分、左旋多巴制剂等效剂量(LDE)、CESD分值均显著升高(均P0.001);睡眠障碍组与对照组比较UPDRS第3部分评分、LDE、CESD分值均无显著差异(均P0.05)。多参数Logistic回归显示,UPDRS第3部分评分和CESD分值能预测疲劳的发生,而LDE未被引入疲劳预测模型。与之相反,UPDRS第3部分评分、LDE、CESD分值均不能预测睡眠障碍的发生。结论疲劳和睡眠障碍是PD常见的非运动症状。二者在临床上有所重叠,但危险因素不同,疲劳和睡眠障碍是PD独立的非运动症状。     

早期帕金森病患者快速眼动睡眠期行为障碍研究

目的探讨早期帕金森病患者快速眼动睡眠期行为障碍发生情况,以及帕金森病运动症状、非运动症状和快速眼动睡眠期行为障碍特点。方法共60例原发性帕金森病患者,采用统一帕金森病评价量表第二和第三部分(UPDRSⅡ和UPDRSⅢ)以及Hoehn-Yahr分期评价帕金森病非运动症状和运动症状,蒙特利尔认知评价量表评价认知功能,汉密尔顿焦虑量表和汉密尔顿抑郁量表评价焦虑和抑郁症状;中文版快速眼动睡眠期行为障碍筛查量表判断是否伴快速眼动睡眠期行为障碍,Epworth嗜睡量表(ESS)评价白天过度嗜睡程度;多导睡眠图监测睡眠障碍特征,包括下颌位相性肌电活动密度和快速眼动睡眠期肌肉失弛缓。结果 60例帕金森病患者中42例(70%)伴快速眼动睡眠期行为障碍(PD+RBD组),多导睡眠图监测其异常行为主要表现为上肢伸展抓握、肢体震颤抽搐、发笑、喊叫和怒骂等非暴力动作,仅2例出现暴力击打、蹬踢等异常行为。PD+RBD组患者年龄(P=0.024)、病程8年比例(P=0.000)、UPDRSⅡ(P=0.005)和UPDRSⅢ(P=0.001)评分、Hoehn-Yahr分期2级比例(P=0.007)、焦虑障碍(P=0.044)和抑郁障碍(P=0.001)比例,以及下颌位相性肌电活动密度(P=0.000)和快速眼动睡眠期肌肉失弛缓比例(P=0.000)均高于对照组,其中,PD+RBD组有16例(38.10%)快速眼动睡眠期行为障碍症状早于帕金森样症状5.20(3.91,6.51)年。结论年龄大、病程长、运动症状和非运动症状严重的帕金森病患者易伴发快速眼动睡眠期行为障碍,快速眼动睡眠期行为障碍可能是帕金森病的早期表现。多导睡眠图监测对早期帕金森病伴快速眼动睡眠期行为障碍的诊断有重要参考价值。     

帕金森病伴发睡眠障碍的临床特点、相关因素及视频多导睡眠图的变化

目的探讨帕金森病(PD)患者伴发睡眠障碍(SD)的临床特点、相关因素、视频多导睡眠图(v-PSG)变化及其对患者生活质量的影响。方法收集2014-06—2016-06就诊于北京天坛医院老年病科的94例PD患者,记录患者的人口学资料。采用匹茨堡睡眠质量指数量表(PSQI)评估患者的睡眠状况,根据评测结果将患者分为PD伴发SD组(PSQI≥5分,PD-SD组)及未伴发SD组(PSQI5分,PD-NSD组)。对PD患者进行统一帕金森病评分量表第三部分(UPDRS-Ⅲ)、蒙特利尔认知评估量表(MoCA)、简易精神状态检查量表(MMSE)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、爱泼沃斯思睡量表(ESS)、疲劳严重度量表(FSS)、UPDRSⅡ量表、日常生活能力量表(ADL)、39项PD生活质量问卷(PDQL-39)及PSQI评分检测,比较两组患者运动症状、非运动症状、生活质量以及睡眠质量等变化。结果 (1)94例PD患者中57例(60.64%)存在SD。(2)PD-SD组和PD-NSD组在性别构成、年龄、起病年龄、受教育水平及病程方面比较均无统计学差异(P0.05)。(3)PSQI量表评分结果显示,PD-SD组睡眠质量、睡眠潜伏期、睡眠时间、睡眠效率、SD、使用睡眠药及日间功能障碍评分均较PD-NSD组高(均P0.01)。(4)PD-SD组患者UPDRSⅠ评分、FSS评分、HAMD评分、HAMA评分和ESS评分、UPDRSⅡ评分、ADL评分、PDQL-39评分明显高于PD-NSD组(P0.05或P0.01)。(5)32例PD患者行v-PSG监测,与PD-NSD组比较,PD-SD组总睡眠时间减少(P0.05),睡眠效率及最低血氧饱和度降低(均P0.05)。结论 PD患者SD的发生率较高;PD-SD患者SD更严重,整体睡眠质量更差;SD明显影响PD患者其他非运动症状。     

丘脑底核脑深部电刺激治疗帕金森病抑郁障碍的初步临床研究

目的研究丘脑底核(STN)脑深部电刺激(DBS)治疗帕金森病(PD)抑郁障碍的短期疗效。方法对15例合并抑郁障碍的帕金森病患者丘脑底核进行电极植入,术后3个月进行PD分级量表(UPDRS)运动评分和汉密尔顿抑郁量表(HAMD17)评分,与术前1个月的评价对照。结果术后15例运动功能症状如肢体僵硬、震颤、运动迟缓和姿势平衡障碍改善良好,停药后UPDRS运动评分下降显著(P<0.01)。术后HAMD17总分下降显著(P<0.01),抑郁障碍改善显进2例(HAMD17减分率≥50%),进步7例(HAMD17减分率≥25%)。术后焦虑/躯体化、阻滞、睡眠障碍和体重因子分均显著低于术前(P<0.01),认知障碍因子分与术前无显著性差异(P>0.05)。结论STNDBS可明显改善帕金森病抑郁障碍症状,对焦虑/躯体化和阻滞等症状尤其显著。     

Contribution of aging to the severity of different motor signs in Parkinson disease

BACKGROUND: Evidence does not support the view that Parkinson disease (PD) represents an accelerated aging process; however, the additional contribution of aging to the severity of different motor signs in patients with PD is not known. This knowledge may have implications for clinical trials of neuroprotective agents in PD. OBJECTIVE: To investigate the contribution of aging to the severity of the different motor signs of idiopathic PD. SETTING: Center for Parkinson Disease and Other Movement Disorders of the Columbia University Medical Center and a neurology clinic that primarily served individuals from the Washington Heights-Inwood community in New York City. PATIENTS: Sample of patients with a wide range of disease duration and age. DESIGN: Cross-sectional clinic-based study. Patients with PD were evaluated using the Unified Parkinson Disease Rating Scale (UPDRS). The total UPDRS motor score was divided into 6 motor domains (tremor, rigidity, bradykinesia, facial expression, speech, and axial impairment) and 2 subscores that represented predominantly dopaminergic (subscore A: tremor, rigidity, bradykinesia, and facial expression) and nondopaminergic (subscore B: speech and axial impairment) deficiency. Analyses were performed using linear regression models with the UPDRS motor domains and subscores as the outcomes. The variation (adjusted R(2)) of the outcome variables explained by the inclusion of disease duration in the models, adjusting for sex, years of education, levodopa dosage, and use of other antiparkinsonian medications, was calculated. The additional variation explained by adding age at examination to the models was used to gauge the contribution of aging to each motor domain and subscore of the UPDRS. RESULTS: A total of 451 patients participated in the study. Mean age at examination was 62.0 years (SD, 12.6 years; median, 62.0 years; range, 18-93 years), and mean disease duration was 7.2 years (SD, 5.9 years; median, 5.6 years; range, 0.1-41.6 years). The additional variation of the outcome variable explained by including age in the models was higher for subscore B (14.3%; 95% confidence interval [CI], 9.9%-20.4%) than subscore A (4.7%; 95% CI, 2.0%-9.1%). Among the 6 motor domains, the additional variation of the outcome variable explained by including age in the models was highest for axial impairment (13.6%; 95% CI, 9.4%-19.6%). CONCLUSION: Axial (gait and postural) impairment in PD may result from the combined effect of the disease and the aging process on nondopaminergic subcortical structures.     

单侧丘脑底核电刺激治疗偏侧型帕金森病的长期疗效

目的评估单侧丘脑底核(STN)脑深部电刺激(DBS)治疗偏侧型帕金森病的长期疗效。方法回顾性分析23例偏侧型帕金森病病人的临床资料,均行单侧STN-DBS治疗,并分别于术前3~5 d、术后1年、术后5年以帕金森病统一评分量表(UPDRS)进行评估。结果术后5年,病人在刺激"关"状态下,UPDRSⅡ、Ⅲ和轴性症状评分较术前明显升高(P<0.05);而刺激"开"状态下,UPDRSⅡ、Ⅲ和轴性部分评分较同期刺激"关"状态分别降低37.37%、41.14%和26.91%。与术前比较,术后5年平均每日口服左旋多巴等效剂量降低24.92%,而异动时间和异动病残度分别增加52.63%和59.65%。本组未发生手术相关并发症,随访期间出现发声困难6例。结论对偏侧型帕金森病人,单侧STN-DBS是一种疗效持久的治疗方法。     

脑白质病变对老年轻度帕金森样体征的影响

目的探讨脑白质病变（WMLs）对老年轻度帕金森样体征（MPSs）的影响。方法临床收集335名老年男性，根据MRIT2加权像将WMLs分为4级，以WMLs0级作为对照组，所有受试者进行UP—DRS运动评定，比较不同程度WMLs组UPDRS运动总评分及各单项评分之间的差异。结果（1）与WMLs0级组比较，WMLs2级组UPDRS运动总分、运动迟缓及轴性损害单项评分显著增加（P〈0．05），WMLs3级组UPDRS运动总分、强直、运动迟缓和轴性损害单项评分显著增加（P〈0．05）；与WMLs1级组比较，WMLs2级组UPDRS运动总分、轴性损害单项评分显著增加（P〈0．05），WMI。S3级组UPDRS运动总分、强直、运动迟缓及轴性损害单项评分显著增加（P〈0．05）；与WMLs2级组比较，WMLs3级组UPDRS运动总分、运动迟缓和轴性损害单项评分显著增加（P〈0．05）；（2）logistic回归分析控制了年龄、高血压病、糖尿病后，轻度帕金森样体征尤其运动迟缓和轴性损害与WMLs2～3级密切相关。结论中到重度WMLs会导致或者加重老年MPSs，尤其运动迟缓和轴性损害症状，而较少产生震颤；轻度WMLs相对是一种良性病变；积极防治WMLs可能会改善老年人的MPSs。     

影响帕金森病患者生活质量的相关因素和分析

目的：研究影响帕金森病（PD）患者生活质量的相关因素。方法：对92例门诊PD患者，采用PDQ-39、UPDRS Ⅰ-Ⅳ、H＆Y、SE、MMSE、HAMD（17项）和HAMA（14项）分别进行评定，并进行统计学分析。结果：PDQ39（PDQ运动能力、PDQ日常生活、PDQ情绪健康、PDQ耻辱感及PDQ社会支持）、UPDRS（Ⅱ和Ⅲ）、医药费用支出、抑郁和焦虑情绪、认知水平以及左旋多巴每日剂量等均是影响生活质量的主要因素。同时女性比男性更易有耻辱感；〈55岁和〉65岁的患者的生活质量更差。结论：运用药物改善PD患者的运动障碍是提高生活质量的重要前提，但同时还要关注患者的情绪、社会功能等情况，尤其对女性、年龄〉55岁和〈65岁的患者。     

Motor impairment in PD: relationship to incident dementia and age

OBJECTIVE: To analyze the relationship of specific motor impairment in idiopathic PD to incident dementia. BACKGROUND: The total Unified PD Rating Scale (UPDRS) motor score at baseline has been associated with an increased risk of developing dementia in PD. METHODS: A cohort of 214 nondemented community-dwelling patients with PD was followed annually with neurologic and neuropsychological evaluations. The association of baseline motor impairment with incident dementia was analyzed using Cox proportional hazards models. Facial expression, tremor, rigidity, and bradykinesia were analyzed as part of subscore A (indicative of dopaminergic deficiency); speech and axial impairment were analyzed as part of subscore B (indicative of predominantly nondopaminergic deficiency). The correlation between the six motor domains and age was also analyzed. RESULTS: Of 173 patients followed for at least 1 year, 50 became demented according to the Diagnostic and Statistical Manual of Mental Disorders, revised 3rd edition (DSM III-R) criteria (mean follow-up, 3.6 +/- 2. 2 years). When both subscores A and B were entered into the Cox model, subscore B was associated with incident dementia (relative risk = 1.19; 95% CI, 1.09 to 1.30; p = 0.0001), in addition to gender, age, and education, whereas subscore A was not (relative risk = 1.03; 95% CI, 0.99 to 1.07; p = 0.19). Of the six motor domains, speech and bradykinesia were associated with incident dementia (p < 0.05), and axial impairment approached significance (p = 0.06). Only axial impairment was correlated with age (correlation coefficient = 0.32; p < 0.001). CONCLUSION: The findings suggest that motor impairment mediated predominantly by nondopaminergic systems is associated with incident dementia in PD. Axial impairment may be the result of a combined effect of the disease and the aging process.     

Cerebral cortical areas in which thickness correlates with severity of motor deficits of Parkinson’s disease

The pathology of Parkinson’s disease (PD) is not confined to the nigrostriatal dopaminergic pathway, but also involves widespread cerebral cortical areas. Such non-nigrostriatal lesions may contribute to disabling dopa-resistant parkinsonian motor deficits. We performed cortical thickness analysis to identify cerebral cortical brain areas in which thickness correlates with the severity of parkinsonian motor deficits. We performed T1-weighted brain magnetic resonance imaging studies in 142 PD patients. Motor scores on the Unified Parkinson’s Disease Rating Scale (UPDRS) were measured, and subscores were calculated for bradykinesia, rigidity, tremor, and axial motor deficits. Using FreeSurfer software, we studied cortical areas in which thickness correlates with disease duration or the severity of parkinsonian motor deficits. The cortical thickness of the parieto-temporal association cortex, including the inferior parietal and posterior parietal cortices, showed a negative correlation with disease duration, total UPDRS motor score, and UPDRS subscores for bradykinesia and axial motor deficits. We found no cortical areas in which thickness correlated with subscores for tremor and rigidity. In addition to nigrostriatal dopaminergic deficit, progressive thinning of the parieto-temporal sensory association cortices related to disease duration seems to be related in part to the exacerbation of bradykinesia and the axial motor symptoms of PD.     

丘脑腹中间核毁损术治疗帕金森病的长期疗效观察

目的探讨丘脑腹中间核（Vim）毁损术治疗帕金森病（PD）的临床疗效及手术并发症。方法PD患者151例在采用MRI丘脑长度比例法定位Vim后行射频热凝毁损Vim治疗。术前、术后1周、1年、3年、6年在未服药状态下行统一PD评定量表Ⅲ（UPDRSⅢ）评分评估疗效。结果不同Hoehn-Yahr分级患者术后1周UPDRSⅢ评分较术前均明显下降（P〈0．05）。术后1周不同级别Hoehn-Yahr分级UPDRSⅢ评分改善率均差异显著术后6年,震颤型和震颤僵直型PD患者UPDRAS评分分别为（35．75±2．30）％和（27．27＋2．02）％;震颤型近期及远期疗效较震颤僵直型好（P〈0．05）。随着Hoehn-Yahr分级的增加和术后时间的延长UPDRSⅢ评分改善率下降。术后并发症包括术后毁损灶少量出血6例,构音功能障碍8例,手术同侧口周及对侧肢体麻木7例。结论经MRI丘脑长度比例法定位后行丘脑Vim毁损术治疗PD近期疗效显著,有较好的远期疗效,并发症较低。     

Randomized trial of pallidotomy versus medical therapy for Parkinson's disease

Thirty-six patients with Parkinson's disease (PD) were randomized to either medical therapy (N = 18) or unilateral GPi pallidotomy (N = 18). The primary outcome variable was the change in total Unified Parkinson's Disease Rating Scale (UPDRS) score at 6 months. Secondary outcome variables included subscores and individual parkinsonian symptoms as determined from the UPDRS. At the six month follow-up, patients receiving pallidotomy had a statistically significant reduction (32% decrease) in the total UPDRS score compared to those randomized to medical therapy (5% increase). Following surgery, patients' showed improvement in all the cardinal motor signs of PD including tremor, rigidity, bradykinesia, gait and balance. Drug-induced dyskinesias were also markedly improved. Although the greatest improvement occurred on the side contralateral to the lesion, significant ipsilateral improvement was also observed for bradykinesia, rigidity and drug-induced dyskinesias. A total of twenty patients have been followed for 2 years to assess the effect of time on clinical outcome. These patients have shown sustained improvement in the total UPDRS (p < 0.0001), "off" motor (p < 0.0001) and complications of therapy subscores (p < 0.0001). Sustained improvement was also seen for tremor, rigidity, bradykinesia, percent on time and drug-induced dyskinesias.     

脐带间充质干细胞移植治疗帕金森病效果分析

目的 探讨脐带间充质干细胞移植治疗帕金森病的临床效果.方法 选择我院收治的38例帕金森病为研究对象,采用足月妊娠产妇脐带处理后干细胞,于第2周期进行鞘内注射移植治疗.分析治疗后临床症状及体征改善情况.治疗前及治疗后1个月,采用帕金森病统一评分量表（UPDRS）对患者精神、行为、情绪、日常活动、运动功能、并发症进行评价.结果 所有患者的静止性震颤、运动迟缓、肌强直、姿势步态障碍均不同程度缓解,治疗过程中及治疗后患者各项生命体征均较平稳.38例患者移植后UPDRS评分显著低于移植前,差异有统计学意义（P＜0.05）.治疗过程中患者有低热、头痛、腰痛、兴奋症状出现,给予对症处理后均完全缓解.均未见抗移植物宿主病.结论 脐带间充质干细胞移植可显著改善帕金森病患者的临床症状.     

立体定向选择性Vim核和(或)PVP核毁损术治疗帕金森病疗效观察

目的观察应用立体定向脑内核团毁损术治疗帕金森病的临床疗效。方法 2012年7至2013年12月采用立体定向丘脑腹中间核(Vim核)和或苍白球腹后外侧部(PVP核)毁损术治疗帕金森病45例。术前、术后1个月进行UPDRS评分,比较手术前后评分的变化和症状改善情况。结果 45例帕金森病患者的肢体震颤、僵硬及运动迟缓均得到明显改善,术后1个月的UPDRS评分较术前明显减少(P0.01),术后无明显并发症。结论立体定向脑内核团毁损术治疗帕金森病疗效显著,靶点定位、毁损范围及程度与手术疗效及并发症密切相关。